Clinical Research Papers:

Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study

Masahito Nakano _, Masatoshi Tanaka, Ryoko Kuromatsu, Hiroaki Nagamatsu, Manabu Satani, Takashi Niizeki, Shusuke Okamura, Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Yu Noda, Hironori Koga, Takuji Torimura and Kurume Liver Cancer Study Group of Japan

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:64400-64409. https://doi.org/10.18632/oncotarget.10794

Metrics: PDF 1591 views  |   HTML 2376 views  |   ?  


Masahito Nakano1, Masatoshi Tanaka2, Ryoko Kuromatsu1, Hiroaki Nagamatsu3, Manabu Satani1, Takashi Niizeki1, Shusuke Okamura1, Hideki Iwamoto1, Shigeo Shimose1, Tomotake Shirono1, Yu Noda1, Hironori Koga1, Takuji Torimura1, for the Kurume Liver Cancer Study Group of Japan

1Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan

2Yokokura Hospital, Miyama, Fukuoka, Japan

3Yame General Hospital, Yame, Fukuoka, Japan

Correspondence to:

Masahito Nakano, email: [email protected]

Keywords: sorafenib, hepatocellular carcinoma, progressive disease, follow-up treatments

Received: February 08, 2016    Accepted: June 30, 2016    Published: July 23, 2016


Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC patients with progressive disease (PD) derive from sorafenib treatment. This study aimed to assess survival risk factors and evaluate therapeutic strategies for advanced HCC patients with PD after sorafenib treatment. We analyzed the clinical data and treatment outcomes for 315 consecutive advanced HCC patients treated with sorafenib. Univariate analyses of overall survival identified therapeutic effect as an independent risk factor in all patients. Among all patients, 141 developed PD. Of those, 58 (41%) were treated with sorafenib monotherapy, 70 (50%) with agents other than sorafenib, and 13 (9%) were not treated at all. The median survival time was 6.1 months for PD patients with sorafenib monotherapy and 12.2 months for those administered alternative treatments (p < 0.0001). Our results indicated that sorafenib treatment may have negative long-term therapeutic effects in advanced HCC patients with PD, and that alternative treatments should be considered for these patients after sorafenib administration.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10794